Overview

Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate in Patients With Stable Severe Renal Disease.

Status:
Completed

Trial end date:
2013-12-01

Target enrollment:

Participant gender:

Summary

The study to be conducted is a prospective, open label trial. It is designed to evaluate the pharmacokinetic/pharmacodynamic and coagulation parameters and safety of dabigatran etexilate in patients with chronic kidney disease.

Phase:

Phase 1

Details

Lead Sponsor:

Boehringer Ingelheim

Treatments:

Dabigatran